Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, People's Republic of China.
Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, People's Republic of China.
Mol Biol Rep. 2023 Jun;50(6):4955-4963. doi: 10.1007/s11033-023-08449-7. Epub 2023 Apr 20.
Overexpression of lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been found in various solid cancers and is associated with disease progression, metastasis, and recurrence. However, the expression pattern of LPCAT1 in acute myeloid leukemia (AML) bone marrow remains unknown. The present study aimed to compare LPCAT1 expression differences in bone marrow samples from AML patients and healthy controls and assess the clinical relevance of LPCAT1 in AML.
LPCAT1 expression in bone marrow was significantly lower in AML than in healthy controls predicted by public databases. Furthermore, real-time quantitative PCR (RQ-PCR) validated that LPCAT1 expression in bone marrow was significantly down-regulated in AML compared to healthy controls [0.056 (0.000-0.846) vs 0.253 (0.031-1.000)]. The DiseaseMeth version 2.0 and The Cancer Genome Atlas analysis revealed that the LPCAT1 promoter was hypermethylated in AML, and there was a strong negative correlation between LPCAT1 expression and methylation (R = - 0.610, P < 0.001). RQ-PCR revealed that the frequency of LPCAT1 low expression was lower in the FAB-M4/M5 subtype than in the other subtypes (P = 0.018). The ROC curve revealed that LPCAT1 expression could serve as a potential diagnostic marker for differentiating AML from controls with an area under the ROC curve of 0.819 (95% CI 0.743-0.894, P < 0.001). In cytogenetically normal AML, patients with LPCAT1 low expression had significantly longer overall survival than those without LPCAT1 low expression (median 19 versus 5.5 months, P = 0.036).
LPCAT1 is down-regulated in AML bone marrow, and LPCAT1 down-regulation could be used as a potential biomarker for AML diagnosis and prognosis.
已发现溶血磷脂酰胆碱酰基转移酶 1（LPCAT1）在各种实体瘤中过度表达，与疾病进展、转移和复发有关。然而，急性髓系白血病（AML）骨髓中 LPCAT1 的表达模式尚不清楚。本研究旨在比较 AML 患者和健康对照者骨髓中 LPCAT1 表达差异，并评估 LPCAT1 在 AML 中的临床相关性。
公共数据库预测 AML 患者骨髓中 LPCAT1 的表达明显低于健康对照组。此外，实时定量 PCR（RQ-PCR）验证 AML 患者骨髓中 LPCAT1 的表达明显低于健康对照组[0.056（0.000-0.846）比 0.253（0.031-1.000）]。DiseaseMeth 版本 2.0 和癌症基因组图谱分析显示 AML 中 LPCAT1 启动子呈高甲基化，LPCAT1 表达与甲基化呈强负相关（R= -0.610，P<0.001）。RQ-PCR 显示 LPCAT1 低表达频率在 FAB-M4/M5 亚型中低于其他亚型（P=0.018）。ROC 曲线显示 LPCAT1 表达可作为区分 AML 与对照组的潜在诊断标志物，ROC 曲线下面积为 0.819（95%CI 0.743-0.894，P<0.001）。在核型正常的 AML 中，LPCAT1 低表达患者的总生存期明显长于无 LPCAT1 低表达患者（中位数 19 个月与 5.5 个月，P=0.036）。
AML 骨髓中 LPCAT1 下调，LPCAT1 下调可作为 AML 诊断和预后的潜在生物标志物。
